Ibex Decision Support
Empower pathologists to make quicker and more accurate diagnosis with state-of-the-art decision-support tools
From the press
The companies collaborate to enhance quality and efficiency in routine cancer diagnosis
Read More
From the press
Ibex’s AI technology helps physicians and providers diagnose cancer with greater real-time accuracy by reducing error and misdiagnosis
Read More
From the press
Digital and computational pathology professional, Richard Nicholson, is appointed as Sales Director for the UK and Ireland
Read More
From the press
Digital pathology industry veteran, Joel Duckworth will lead Ibex’s growth in the Americas as Chief Revenue Officer
Read More
From the press
Ibex’s Galen™ Breast is rolled out as a first read application, helping pathologists improve accuracy, reduce turnaround time and streamline reporting
Read More
From the press
Globally renowned oncology center Institut Curie is leading a study on Ibex’s Galen™ Breast, the first AI-based solution used by pathologistsb in routine clinical practice for breast cancer detection.
Read More
From the press
Ibex strengthens its focus on the US market with seasoned health executives to accelerate delivery of its AI-powered cancer diagnosis vision to healthcare networks, payors and policy makers
Read More
From the press
The ISO 13485 certification validates Ibex Medical Analytics’ position as a leading and quality-focused solution provider for healthcare organizations
Read More
From the press
Ibex was selected among the first ever winners of the AI in Health and Care Award, sharing £50 million to enable a study of Ibex’s AI technology across multiple NHS trusts
Read More
Ibex has been playing an important role in advancing AI-based technologies in pathology and is the first company to implement an AI-driven diagnostic system in routine clinical use. I am a huge advocate of the work of this company.
Sylvia L. Asa, MD, MPH
Former USCAP President and Chief Pathologist at UHN Toronto
I am deeply impressed with the Ibex Second Read system and with the performance of its algorithms, as well as with how quickly the Ibex team was able to deploy a system and integrate it into the routine clinical workflow of a large pathology institute. This disruptive technology is a game-changer.
Daniel Val Garijo, MD
Pathologist, Laboratoire National de Santé, Luxembourg
I’m extremely happy to be collaborating with Ibex on transforming cancer diagnostics – and thrilled to have deployed the Ibex Second Read system at Maccabi, rendering the Maccabi pathology institute the first in the world to deploy such a system in our routine workflow, and the first to demonstrate the value of AI in reversing a missed cancer diagnosis in real time.
Prof. Varda Shalev, MD, MPH
Managing Director, Morris Kahn & Maccabi Research and Innovation Institue at Maccabi Health care Services
The advent of digital pathology enables the implementation of AI-driven technologies to ensure more accurate and rapid cancer diagnosis in pathology institutes. We believe that systems such as the one developed by Ibex have an important role in advancing routine anatomic pathology practice. We will be assessing the performance of the Ibex Second Read system to determine its potential for implementation at UPMC.
